biostudies-literatureMunoz-Martinez SCancer Research UKInstituto de Salud Carlos IIIEuropean Association for the Study of the LiverWellcome Trust1891-1901https://www.ebi.ac.uk/biostudies/studies/S-EPMC9347559biostudies-literatureUnknown42(8)<h4>Background & aims</h4>Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.<h4>Methods</h4>Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.<h4>Results</h4>Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage aLiver international : official journal of the International Association for the Study of the LiverOutcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.PMC9347559PS3416CD18/00126C9380/A18084C9380/A26813PI15/00145FI19/00222RCCPDB‐Nov21/100008C18342/A23390PI19/0081916‐0026PI18/0358PI044031PI18/00768PI18/00542PI13/01229Tawheed AWatson RVarela MRios JHollande CVergara MMello VSapena VLachenmayer AVillani RBandi JCRodriguez-Lope CBruix JGuarino MGonzalez Santiago JMBlaise LAcevedo JAlves RCPda Fonseca LCarrilho FJNault JCLeal CRGPeck-Radosavljevic MRojas AAlvares-da-Silva MRReig MVilgrain VAlqahtani SAIavarone MPascual SFerguson Theodoro CElvevi AAnders MTacke FViera-Alves DEFranca AReeves HLMocan TMunoz-Martinez SSanduzzi-Zamparelli MBraconi CBouattour MLozano MForner AEl-Kassas MGarcia-Juarez ICabibbo GSparchez ZMoctezuma-Velazquez CPinero FPerello CPinato DJD'Alessio ASala MRimassa LfalseOutcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.<h4>Background & aims</h4>Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.<h4>Methods</h4>Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.<h4>Results</h4>Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage a2022-01-01T00:00:00Z2022 Aug2025-04-19T05:58:55.163Z2024-11-09T16:12:40.075ZS-EPMC93475593560893910.1111/liv.15320